Employing novel humanized murine strains to develop hematopoietic stem cell gene therapeutic approaches for very early-onset inflammatory bowel disease due to IL10-receptor deficiency.

采用新型人源化小鼠品系开发造血干细胞基因治疗方法,用于治疗因 IL10 受体缺陷所致的极早发炎症性肠病。

基本信息

  • 批准号:
    9535567
  • 负责人:
  • 金额:
    $ 40.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-08-08 至 2019-07-31
  • 项目状态:
    已结题

项目摘要

Loss-of-function mutations in interleukin-10 (IL10) or the IL10 receptor (IL10R) lead to a life-threatening immune deficiency presenting as severe very early-onset inflammatory bowel disease (VEO-IBD). IL10 is an immunosuppressive cytokine that is secreted by a variety of hematopoietic cells, primarily myeloid, B and T cells, which reduces inflammation, at least in part by limiting the secretion of pro-inflammatory cytokines. The receptor for IL10 is composed of two IL10R1 and two IL10R2 chains and is expressed predominantly on hematopoietic cells. Mice deficient for either IL10R or IL10 develop spontaneous colitis and similarly, patients with loss-of-function mutations of either the IL10RA or IL10RB develop severe VEO-IBD. Recent studies have shown that hematopoietic stem cell (HSC) transplantation (HSCT) may lead to a sustained remission of the disease, but allogeneic HSCT carries significant risks of acute toxicities and graft-versus-host-disease (GVHD) and requires a suitable HLA-matched donor. Preliminary data from our group has indicated that Il10rb gene transfer into IL10Rβ-deficient bone marrow precursors followed by HSCT into IL10Rβ knockout models can prevent the development of IBD. We propose to use gene transfer into autologous HSCs via lentivirus vectors (permitting either ubiquitous or lineage-specific Il10rb expression) to restore IL10R signaling and provide an alternative treatment option. In this proposal, we will develop and optimize lentivirus vectors to express Il10rb, determine the in vitro and in vivo efficacy and safety of these vectors in established murine knockout models. In addition, we will utilize novel humanized mouse models recently developed that permits the use of patient derived CD34+ HSCs to assess both the functional consequence of IL10R2 deficiency in human cells in vivo as well as the effectiveness of gene transfer in patient-derived HSCs. Moreover, we plan to generate CRISPR- Cas9 gene-edited HSCs derived from IL10R1- and IL10R2-deficient human patients and assess the frequency and precision of editing events and functional consequences. These investigations will provide the preclinical data clarifying the transgenic expression levels needed for correcting the immune dysregulation and the safety of expressing a signaling molecule in hematopoietic cells. Finally, we will determine in both standard IL10Rβ- deficient murine as well as humanized mouse models, transplanted with murine- and patient-derived IL10Rβ/IL10R2-deficient HSCs with lineage-specific Il10rb/IL10RB-expressing lentivirus vectors, the precise cell populations that require IL10Rβ expression to correct immune dysfunction. These studies will enhance our understanding of the basic cellular pathobiology of this rare disease and also address the complexities associated with heterologous expression of transgene in specific components of the hematopoietic compartment. Deep expertise in gene therapy (Williams) and immunology/IBD (Snapper) will form an excellent basis to develop a gene therapy approach for this indication.
白细胞介素-10(IL 10)或IL 10受体(IL 10 R)的功能缺失突变导致危及生命的 免疫缺陷表现为严重的极早发型炎症性肠病(VEO-IBD)。IL 10是一种 由多种造血细胞分泌免疫抑制细胞因子,主要是骨髓、B和T细胞 细胞,其至少部分地通过限制促炎细胞因子的分泌来减少炎症。的 IL 10受体由两条IL 10 R1和两条IL 10 R2链组成,主要在 造血细胞缺乏IL 10 R或IL 10的小鼠发展为自发性结肠炎,类似地,患者 具有IL 10 RA或IL 10 RB的功能丧失突变的患者发展为严重的VEO-IBD。最近的研究 表明造血干细胞(HSC)移植(HSCT)可能导致持续缓解的 但是同种异体造血干细胞移植具有显著的急性毒性和移植物抗宿主病(GVHD)风险 并且需要合适的HLA匹配的供体。本研究组的初步数据表明,Il 10 rb基因 转移到IL 10 R β缺陷的骨髓前体中,然后进行HSCT到IL 10 R β敲除模型中, 预防IBD的发展。我们建议通过慢病毒载体将基因转移到自体HSC中 (允许普遍存在的或谱系特异性的Il 10 rb表达)以恢复IL 10 R信号传导并提供免疫应答。 替代治疗方案。在本研究中,我们将开发和优化慢病毒载体来表达IL 10 rb, 确定这些载体在已建立的鼠基因敲除模型中的体外和体内功效和安全性。 此外,我们将利用最近开发的新的人源化小鼠模型,该模型允许使用患者模型。 衍生的CD 34 + HSC来评估体内人细胞中IL 10 R2缺陷的功能后果, 以及基因转移在患者来源的HSC中的有效性。此外,我们计划生成CRISPR- Cas9基因编辑的HSC来源于IL 10 R1和IL 10 R2缺陷的人类患者,并评估其频率 以及编辑事件和功能后果的精确性。这些研究将提供临床前 阐明校正免疫失调所需的转基因表达水平和安全性的数据 在造血细胞中表达一种信号分子。最后,我们将在两种标准IL 10 R β- 缺陷鼠以及人源化小鼠模型,移植鼠和患者来源的 IL 10 R β/IL 10 R2缺陷型HSC与谱系特异性IL 10 rb/IL 10 RB表达慢病毒载体,精确表达IL 10 R β/IL 10 R2缺陷型HSC。 需要IL 10 R β表达以纠正免疫功能障碍的细胞群。这些研究将加强我们的 了解这种罕见疾病的基本细胞病理学,并解决其复杂性。 与造血干细胞的特定成分中转基因的异源表达相关, 车厢在基因治疗(威廉姆斯)和免疫学/IBD(斯纳珀)方面的深厚专业知识将形成一个优秀的 为该适应症开发基因治疗方法奠定了基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Scott B Snapper其他文献

Efficacy and Safety of Anti-Tumor Necrosis Factor Alpha in Very Early Onset Inflammatory Bowel Disease.
抗肿瘤坏死因子α在极早发炎症性肠病中的功效和安全性。
  • DOI:
    10.1093/ibd/izad196
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    4.9
  • 作者:
    L. Collen;V. Mitsialis;David Y. Kim;Mairead Bresnahan;Jessica Yang;M. Tuthill;A. Combs;J. Barends;M. Field;Enju Liu;R. Bearup;I. Okoroafor;Christoph Klein;A. Muise;A. Bousvaros;J. Ouahed;Scott B Snapper
  • 通讯作者:
    Scott B Snapper
Discordance between a deep learning model and clinical-grade variant pathogenicity classification in a rare disease cohort
罕见疾病队列中深度学习模型与临床级变异致病性分类之间的不一致
  • DOI:
    10.1101/2024.05.22.24307756
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    S. Kong;In;Lauren V Collen;Arjun K Manrai;Scott B Snapper;Kenneth D Mandl
  • 通讯作者:
    Kenneth D Mandl

Scott B Snapper的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Scott B Snapper', 18)}}的其他基金

Type III interferon Control of Mucosal Immunity
III 型干扰素控制粘膜免疫
  • 批准号:
    10587625
  • 财政年份:
    2017
  • 资助金额:
    $ 40.79万
  • 项目类别:
Exploring Regulatory T Cell Dysfunction in a Murine Model of Colitis
探索小鼠结肠炎模型中的调节性 T 细胞功能障碍
  • 批准号:
    8232674
  • 财政年份:
    2011
  • 资助金额:
    $ 40.79万
  • 项目类别:
Deciphering the Role of WASP Family Proteins in T Cell Function
解读 WASP 家族蛋白在 T 细胞功能中的作用
  • 批准号:
    8147996
  • 财政年份:
    2010
  • 资助金额:
    $ 40.79万
  • 项目类别:
Exploring Regulatory T Cell Dysfunction in a Murine Model of Colitis
探索小鼠结肠炎模型中的调节性 T 细胞功能障碍
  • 批准号:
    7877475
  • 财政年份:
    2009
  • 资助金额:
    $ 40.79万
  • 项目类别:
Cytoskeletal-Pathogen Interactions in Shigella Infection
志贺氏菌感染中的细胞骨架-病原体相互作用
  • 批准号:
    6800508
  • 财政年份:
    2003
  • 资助金额:
    $ 40.79万
  • 项目类别:
Cytoskeletal-Pathogen Interactions in Shigella Infection
志贺氏菌感染中的细胞骨架-病原体相互作用
  • 批准号:
    6833455
  • 财政年份:
    2003
  • 资助金额:
    $ 40.79万
  • 项目类别:
Cytoskeletal-Pathogen Interactions in Shigella Infection
志贺氏菌感染中的细胞骨架-病原体相互作用
  • 批准号:
    7161772
  • 财政年份:
    2003
  • 资助金额:
    $ 40.79万
  • 项目类别:
Cytoskeletal-Pathogen Interactions in Shigella Infection
志贺氏菌感染中的细胞骨架-病原体相互作用
  • 批准号:
    6630241
  • 财政年份:
    2003
  • 资助金额:
    $ 40.79万
  • 项目类别:
Cytoskeletal-Pathogen Interactions in Shigella Infection
志贺氏菌感染中的细胞骨架-病原体相互作用
  • 批准号:
    7012813
  • 财政年份:
    2003
  • 资助金额:
    $ 40.79万
  • 项目类别:
The Pathogenesis Of Colitis In A Novel Th2 Model Of IBD
新型 IBD Th2 模型中结肠炎的发病机制
  • 批准号:
    6418028
  • 财政年份:
    2002
  • 资助金额:
    $ 40.79万
  • 项目类别:

相似海外基金

HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
  • 批准号:
    10039902
  • 财政年份:
    2022
  • 资助金额:
    $ 40.79万
  • 项目类别:
    EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
  • 批准号:
    21K15925
  • 财政年份:
    2021
  • 资助金额:
    $ 40.79万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
  • 批准号:
    21K08410
  • 财政年份:
    2021
  • 资助金额:
    $ 40.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
  • 批准号:
    20K21672
  • 财政年份:
    2020
  • 资助金额:
    $ 40.79万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
  • 批准号:
    18K16395
  • 财政年份:
    2018
  • 资助金额:
    $ 40.79万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
  • 批准号:
    17K10951
  • 财政年份:
    2017
  • 资助金额:
    $ 40.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
  • 批准号:
    370541
  • 财政年份:
    2017
  • 资助金额:
    $ 40.79万
  • 项目类别:
    Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
  • 批准号:
    16K10863
  • 财政年份:
    2016
  • 资助金额:
    $ 40.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
  • 批准号:
    276706135
  • 财政年份:
    2015
  • 资助金额:
    $ 40.79万
  • 项目类别:
    Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
  • 批准号:
    15H04915
  • 财政年份:
    2015
  • 资助金额:
    $ 40.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了